Genmab A/S (Nasdaq: GMAB; 0MGB), the Copenhagen-headquartered international biotechnology company, has published a formal disclosure of share transactions conducted by managerial employees and their closely associated persons, in compliance with Article 19 of EU Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. The announcement, dated 12 November 2026, was filed via a company announcement originating from Copenhagen, Denmark. Genmab's managerial employees have granted the company power of attorney to publish trading activity on their behalf, a standard mechanism under EU market abuse rules. Investors tracking insider transaction patterns at the antibody-focused biotech will note this filing as part of Genmab's ongoing regulatory transparency obligations.

Key Points

  • Genmab A/S (Nasdaq: GMAB; 0MGB) — Copenhagen-headquartered international biotechnology company
  • Disclosure of managerial employee and closely associated persons' share transactions filed under EU Market Abuse Regulation Article 19
  • Specific transaction volumes, values, and individual names were not disclosed in the body of the announcement; details are contained within an attached document titled "121126_CA49_Managerial Employee Transactions"
  • Investors should review the attached transaction document for specific trade details and monitor subsequent filings for further insider activity

Genmab's Regulatory Obligation to Disclose Insider Trades Under EU MAR Article 19

Under Article 19 of EU Market Abuse Regulation No. 596/2014, persons discharging managerial responsibilities at listed companies — alongside their closely associated persons — are legally required to notify both the relevant competent authority and the issuer of transactions conducted in the company's securities. Genmab has implemented a power-of-attorney arrangement whereby managerial employees authorise the company itself to publish these disclosures on their behalf. This structure is a commonly adopted compliance mechanism among European-listed biotechnology and pharmaceutical firms seeking to streamline their MAR reporting obligations and maintain consistent, timely transparency with investors and regulators.

Genmab's Antibody Medicine Portfolio and Global Biotechnology Operations

Established in 1999, Genmab has grown into an international biotechnology business focused on developing innovative antibody medicines targeting cancer and other serious diseases. The company's platform spans multiple therapeutic formats, including bispecific antibodies, antibody–drug conjugates, immune-modulating antibodies, and other next-generation modalities. Its science underpins eight approved antibody medicines currently on the market. Genmab maintains a late-stage clinical pipeline that includes wholly owned programmes. The company operates from its headquarters in Valby, Copenhagen, with an international presence spanning North America, Europe, and Asia Pacific — a footprint that reflects its ambition to deliver transformative medicines globally.

Transaction Detail Contained in Attached Filing; Specific Figures Not Published in Announcement Body

The announcement itself does not set out the specific number of shares traded, the individuals involved, the transaction prices, or the aggregate value of trades disclosed. Those details are reserved for the attached document, titled "121126_CA49_Managerial Employee Transactions", which forms part of the formal regulatory filing. The company did not disclose these figures in the announcement body. Investors and analysts wishing to assess the scale or direction of insider trading activity at Genmab will need to consult the full attachment for precise transaction-level data as required under Implementing Regulation 2016/523.